NASDAQ:ARDS Aridis Pharmaceuticals (ARDS) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 01:31 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About Aridis Pharmaceuticals Stock (NASDAQ:ARDS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aridis Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.00▼$0.05Volume592 shsAverage Volume24,390 shsMarket Capitalization$5.33 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aridis Pharmaceuticals is a biopharmaceutical company focused on developing antibody-based treatments for infectious diseases, particularly serious bacterial and respiratory infections. Its work has included therapies intended to complement antibiotics by targeting toxins or other components of disease-causing bacteria. The company’s research programs have included AR-301, a monoclonal antibody targeting Staphylococcus aureus alpha toxin, investigated as a potential treatment for severe pneumonia. Aridis has also developed other antibody candidates for infectious diseases using its antibody-discovery technologies. Founded in 2003 and based in San Jose, California, Aridis was founded by Vu Truong, who has served as the company’s chief executive officer. Its development programs have been conducted primarily in the United States.AI Generated. May Contain Errors. Read More Receive ARDS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARDS Stock News HeadlinesAridis Pharmaceuticals, Inc. (ARDS) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comAridis Provides Corporate UpdateDecember 20, 2024 | globenewswire.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 19 at 1:00 AM | Porter & Company (Ad)Horizon Tech Finance (NASDAQ:HRZN) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comGenor Biopharma Holdings Limited (67N0.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comBreathing easier: Nature-inspired treatments could relieve acute respiratory distressAugust 3, 2024 | msn.comAridis Provides Corporate UpdateJune 24, 2024 | globenewswire.comIrish Cup: Institute's quarter-final place confirmed as IFA rejects Ards protestFebruary 10, 2024 | bbc.co.ukSee More Headlines ARDS Stock Analysis - Frequently Asked Questions How have ARDS shares performed this year? Aridis Pharmaceuticals' stock was trading at $0.0002 at the beginning of 2026. Since then, ARDS shares have decreased by 50.0% and is now trading at $0.0001. How were Aridis Pharmaceuticals' earnings last quarter? Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($1.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $1.43. The company had revenue of $520 thousand for the quarter. When did Aridis Pharmaceuticals IPO? Aridis Pharmaceuticals (ARDS) raised $28 million in an initial public offering on Tuesday, August 14th 2018. The company issued 2,000,000 shares at $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers. How do I buy shares of Aridis Pharmaceuticals? Shares of ARDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aridis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aridis Pharmaceuticals investors own include Viking Therapeutics (VKTX), Salesforce (CRM), Abeona Therapeutics (ABEO), ADMA Biologics (ADMA), Ardelyx (ARDX), Axcella Health (AXLA) and Aytu BioPharma (AYTU). Company Calendar Today11/19/2026Next Earnings (Estimated)11/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ARDS CIK1614067 Webwww.aridispharma.com Phone(408) 385-1742Fax408-960-3822Employees30Year Founded2003Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares53,321,000Free Float50,388,000Market Cap$5.33 thousand OptionableNot Optionable Beta55.49 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:ARDS) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aridis Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.